Two Sigma Advisers
ABUS icon

Two Sigma Advisers’s Arbutus Biopharma ABUS Stock Holding History

Two Sigma Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,900
Closed -$43K – 2316
2025
Q2 		$43K Buy
13,900
+1,900
+16% +$6.31K ﹤0.01% 2265
2025
Q1 		$41.9K Hold
12,000
– – ﹤0.01% 2330
2024
Q4 		$39.2K Sell
12,000
-1,200
-9% -$4.41K ﹤0.01% 2299
2024
Q3 		$50.8K Sell
13,200
-3,900
-23% -$15K ﹤0.01% 2214
2024
Q2 		$52.8K Sell
17,100
-500
-3% -$1.5K ﹤0.01% 2361
2024
Q1 		$45.4K Sell
17,600
-13,400
-43% -$34.7K ﹤0.01% 2352
2023
Q4 		$77.5K Buy
+31,000
New +$60.7K ﹤0.01% 2353
2023
Q3 		– Sell
-13,700
Closed -$31.5K – 2364
2023
Q2 		$31.5K Buy
+13,700
New +$35.7K ﹤0.01% 2302
2022
Q3 		– Sell
-64,400
Closed -$175K – 2521
2022
Q2 		$175K Sell
64,400
-171,800
-73% -$440K ﹤0.01% 2306
2022
Q1 		$704K Sell
236,200
-108,100
-31% -$331K ﹤0.01% 1815
2021
Q4 		$1.34M Buy
344,300
+228,500
+197% +$888K ﹤0.01% 1399
2021
Q3 		$497K Sell
115,800
-108,800
-48% -$363K ﹤0.01% 1928
2021
Q2 		$681K Sell
224,600
-196,600
-47% -$609K ﹤0.01% 1803
2021
Q1 		$1.4M Buy
+421,200
New +$1.63M ﹤0.01% 1457
2020
Q4 		– Sell
-24,100
Closed -$75K – 2362
2020
Q3 		$75K Sell
24,100
-142,600
-86% -$434K ﹤0.01% 2295
2020
Q2 		$303K Buy
166,700
+32,700
+24% +$53.5K ﹤0.01% 2114
2020
Q1 		$135K Buy
134,000
+53,000
+65% +$143K ﹤0.01% 2260
2019
Q4 		$225K Buy
81,000
+1,700
+2% +$2.75K ﹤0.01% 2152
2019
Q3 		$121K Sell
79,300
-7,100
-8% -$12.2K ﹤0.01% 2098
2019
Q2 		$180K Buy
86,400
+50,800
+143% +$130K ﹤0.01% 2150
2019
Q1 		$127K Buy
35,600
+19,200
+117% +$73.7K ﹤0.01% 2166
2018
Q4 		$63K Buy
16,400
+2,300
+16% +$11.3K ﹤0.01% 2264
2018
Q3 		$133K Buy
+14,100
New +$140K ﹤0.01% 2138

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Advisers's ABUS Position: Q3 2025 in Review

Two Sigma Advisers sold out of Arbutus Biopharma (ABUS) in Q3 2025, closing a stake of 13,900 shares — an estimated $43K sold.

Two Sigma Advisers first reported a position in ABUS in Q3 2018 and held it in 23 quarters. The position peaked at $1.4M in Q1 2021. 166 funds tracked by Wall St. Rank hold ABUS as of Q3 2025.

  • Two Sigma Advisers reported no remaining Arbutus Biopharma position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 13,900 Arbutus Biopharma shares in Q3 2025, an estimated $43K.
  • Two Sigma Advisers first reported a position in Arbutus Biopharma in Q3 2018 and held it in 23 quarters.
  • Two Sigma Advisers's Arbutus Biopharma position peaked at $1.4M in Q1 2021.
  • 166 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.